

Press Release

SYGNIS AG launches TruePrime™ Liquid Biopsy Kit targeting Oncology Research and Diagnostics

- **Selective amplification of circulating tumor DNA**
- **Valuable oncology research tool**
- **Strong diagnostic potential for early stage tumors and tumor monitoring**
- **Targeting fast growing, multi-billion dollar markets**
- **Additional patent application filed**

Madrid, Spain, and Heidelberg, Germany, November 16, 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the launch of its TruePrime™ Liquid Biopsy Kit, a ready to use amplification kit for ct-DNA (circulating tumor DNA), to be used in the detection, analysis and monitoring of early tumor stages.

Liquid biopsy, the analysis of tumor-derived DNA traces in the blood of a patient, has the potential to revolutionize diagnostic medicine, particularly in oncology. Current techniques for cell-free DNA (cf-DNA) analysis are limited due to a lack of sensitivity. These limitations are inherently linked with the low abundance of ct-DNA present in bodily fluid samples, particularly when such samples are to be analysed by next generation sequencing (NGS).

Whilst the underlying technology for the TruePrime™ technology is already covered by granted patents in several jurisdictions and additional patent application to protect this very commercially attractive application has recently been submitted.

In addition to becoming a valuable tool in oncology research this technology will also have utility in the field of precise medicine and has the potential to take up a pivotal role in the diagnosis and monitoring of cancer. The last ten years have seen enormous progress in both the understanding of cancer disease as well as the development of targeted therapies. Liquid biopsy is one of the fastest developing areas in this field, with a huge potential to revolutionize diagnostic medicine. Estimations for the global liquid biopsy market in 2020 range upwards from a conservative \$1.3 billion. SYGNIS's TruePrime™ Liquid Biopsy technology is well positioned to take a central role in the highly valuable market segment.

Heikki Lanckriet co-CEO and CSO of SYGNIS commented: “TruePrime™ Liquid Biopsy is unique in that it selectively amplifies cancerous DNA in blood samples. Moreover the TruePrime™ DNA amplification technology provides higher quality DNA as it amplifies more accurately with less bias than any other DNA amplification technology currently available. It is also 1000 times more sensitive than any other multiple displacement amplification (MDA) technique currently available on the market. Due to these valuable properties the technology is poised to make a momentous impact in the field of oncology research and cancer diagnosis.”

For further information, please contact:

SYGNIS AG

Pilar de la Huerta
Co-CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com

MC Services AG

Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: raimund.gabriel@mc-services.eu

About SYGNIS AG: www.sygnis.com

SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS's product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).

This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###